A phase III trial of GTL 001 against HPV 16/18 infections
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2016
At a glance
- Drugs GTL 001 (Primary)
- Indications Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- 30 Sep 2016 According to a GENTICEL media release, a previous phase II study (Profile 700237810) did not show statistical difference in viral clearance between the treated group and the placebo group in the total population based on which the company has decided not make any further investment towards a phase III program of GTL-001.
- 30 Sep 2016 Status changed from planning to withdrawn prior to enrolment, according to a GENTICEL media release.
- 28 Jan 2016 New trial record